Remix Therapeutics will replace Passage Bio on the Nasdaq in an all-stock reverse merger, with the combined company trading under the ticker RMTX. Remix, a clinical-stage RNA-targeting biotech, will operate under its own name and host its pipeline of small molecule mRNA degraders, including lead candidate REM-422. Passage Bio shareholders will own about 7% of the combined company; Remix will receive roughly $100 million in a concurrent private placement, funding operations into 2028. REM-422, an oral mRNA degrader, targets the MYB transcription factor implicated in several cancers, and is in Phase 1/2 trials for adenoid cystic carcinoma and AML/HR-MDS. The merger is expected to close in Q4 2026, subject to shareholder and regulatory approvals, marking a strategic pivot for Passage Bio from gene therapy to an RNA-focused oncology platform. Sources: Spurned by the FDA, Passage Bio finds an exit through Remix Passage Bio fusioniert mit Remix Therapeutics im Rahmen eines Akti...
- Get link
- X
- Other Apps